Live genetically modified bacteria as drug delivery tools: At the doorstep of a new pharmacology?

Expert Opinion on Biological Therapy

Volumn 4, Issue 4, 2004, Pages 439-441

  Steidler, Lothar ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Cytokine; Drug delivery; Genetic modification; Lactic acid bacteria; ThyA

Indexed keywords

CYTOKINE; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; PROTEIN;

BACTERIAL GROWTH; BACTERIUM; BIOTECHNOLOGY; CLINICAL TRIAL; CROHN DISEASE; DNA MODIFICATION; DRUG DELIVERY SYSTEM; ENTERITIS; EUKARYOTE; EXPERIMENTAL MODEL; HEALTH CARE; HUMAN; LACTIC ACID BACTERIUM; LACTOBACILLUS; LACTOBACILLUS DELBRUECKII; MUCOSA; NONHUMAN; PHYSIOLOGY; PROPHYLAXIS; REVIEW; SIDE EFFECT; STREPTOCOCCUS GORDONII; ULCERATIVE COLITIS;

ANIMALS; ANTINEOPLASTIC AGENTS; BACTERIA; BACTERIAL PHYSIOLOGY; DRUG DELIVERY SYSTEMS; HUMANS; PROTEINS;

ANIMALIA; BACTERIA (MICROORGANISMS); EUKARYOTA; LACTOBACILLUS; LACTOBACILLUS DELBRUECKII; STREPTOCOCCUS; STREPTOCOCCUS GORDONII;

EID: 1842784814     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.4.439     Document Type: Review

References (19)

1. STEIDLER L, HANS W, SCHOTTE L: et al.: Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science (2000) 289(5483):1352-1355. Proof of concept for therapeutic use of GM lactococci.
2. STEIDLER L, ROBINSON K, CHAMBERLAIN L et al.: Mucosal delivery of murine interleukin-2 (IL-2) and IL-6 by recombinant strains of Lactococcus Lactis coexpressing antigen and cytokine. Infect. Immun. (1998) 66(7):3183-3189. First demonstration of protein delivery at the mucosa by GM lactococci.
3. STEIDLER L, WELLS JM, RAEYMAEKERS A, VANDEKERCKHOVE J, FIERS W, REMAUT E: Secretion of biologically active murine interleukin-2 by Lactococcus lactis subsp. lactis. Appl. Environ. Microbiol. (1995) 61(4):1627-1629. First cytokine secreted by GM lactococci.
4. STEIDLER L, FIERS W, REMAUT E: Expression of human and murine interleukins in Lactococcus lactis. In: NATO-ASI series H98 on 'Current Advances in Genetics, Metabolism and Application of Lactic Acid Bacteria'. Bozoglu F, Ray B (Eds), Springer Verlag, Heidelberg (1996):63-79.
5. SCHOTTE L, STEIDLER L, VANDEKERCKHOVE J, REMAUT E: Secretion of biologically active murine interleukin-10 by Lactococcus lactis. Enzyme Microb. Technol. (2000) 27(10):761-765.
6. BENINATI C, OGGIONI MR, BOCCANERA M et al.: Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria. Nat. Biotechnol. (2000) 18(10):1060-1064. Use of GM bacteria for single chain antibody therapy.
7. KRUGER C, HU Y, PAN Q et al.: In situ delivery of passive immunity by lactobacilli producing single-chain antibodies. Nat. Biotechnol. (2002) 20(7):702-706.
8. BERMUDEZ-HUMARAN LG, LANGELLA P, CORTES-PEREZ NG et al.: Intranasal immunization with recombinant Lactococcus lactis Lie& secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production. Infect. Immun. (2003) 71(4):1887-1896.
9. SHANAHAN F: Crohn's disease. Lancet (2002) 359(9300):62-69.
10. VAN DEVENTER SJ, ELSON CO, FEDORAK RN: Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology (1997) 113(2):383-389.
11. FEDORAK RN, GANGL A, ELSON CO et al.: Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology (2000) 119(6):1473-1482.
12. SCHREIBER S, FEDORAK RN, NIELSEN OH et al.: Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology (2000) 119(6):1461-1472.
13. TILG H, ULMER H, KASER A, WEISS G: Role of IL-10 for induction of anemia during inflammation. J. Immunol. (2002) 169(4):2204-2209.
14. TILG H, VAN MONTFRANS C, VAN DEN ENDE A et al.: Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut (2002) 50(2):191-195. Mechanistic insight in failure of systemic IL-10 for Crohn's disease treatment
15. COLOMBEL JF, RUTGEERTS P, MALCHOW H et al.: Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut (2001) 49(1):42-46.
16. SCHREIBER S, FEDORAK RN, NIELSEN OH et al.: Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology (2000) 119(6):1461-1472.
17. MASOOD R, ZHANG Y, BOND MW et al.: Interleukin-10 is an autocrine growth factor for acquired immunodeficiency syndrome-related B-cell lymphoma. Blood (1995) 85(12):3423-3430.
18. STEIDLER L, NEIRYNCK S, HUYGHEBAERT N et al.: Biological containment of genetically modified Lactacoccus lactis for intestinal delivery of human interleukin 10. Nat. Biotechnol. (2003) 21(7):785-789. Biological containment of GM lactococci.
19. ALPERT C-A, MATER DDG, MULLER M-C, OURIET M-F, DUVAL-IFLAH Y, CORTHIER G: Worst-case scenarios for horizontal gene transfer from Lactococcus lactis carrying heterologous genes to Enterococcus faecalis in the digestive tract of gnotobiotic mice. Environ. Biosafety Res. (2004) 2:173-180.